Use of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis
Abstract:: Hypofibrinolysis is a documented abnormality in conditions with high risk of vascular occlusion. A key inhibitor of fibrinolysis is α2-antiplasmin (α2AP), and we hypothesize that the Affimer technology, comprising small conformational proteins with 2 9-amino-acid variable regions, can be...
保存先:
| 主要な著者: | , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2025-01-01
|
| シリーズ: | Blood Advances |
| オンライン･アクセス: | http://www.sciencedirect.com/science/article/pii/S2473952924006414 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|